Krystal Biotech (KRYS) EBT Margin (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly EBT Margin of 55.43% for Q2 2026, up 672.0% year-over-year from 7.18% in Q2 2025, and up 5.0% on a QoQ basis from 52.79% in Q1 2026.
Krystal Biotech (KRYS) EBT Margin (2023 - 2026) Analysis & Trends
Krystal Biotech has reported EBT Margin for 4 years, with the latest figure at 55.43% in Q2 2026.
- EBT Margin for Q2 2026 came in at 55.43%, up 672.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 51.44% (up 446.0% YoY), and the FY2025 annual result was 48.69%, up 1587.0% from the prior year.
- EBT Margin climbed to 55.43% in Q2 2026, from 52.79% in the prior quarter.
- Over five years, EBT Margin peaked at 943.75% in Q3 2023 and troughed at 2.06% in Q1 2024.
- A 4-year average of 115.49% and a median of 48.87% in 2025 frame the typical range for EBT Margin.
- The widest annual swing landed in 2024, when EBT Margin sank 90824 bps; it then surged 4737 bps in 2025.
- A 4-year view of EBT Margin shows it stood at 25.29% in 2023, then jumped by 111 bps to 53.35% in 2024, then decreased by 11 bps to 47.74% in 2025, then rose by 16 bps to 55.43% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 55.43% in Q2 2026, 52.79% in Q1 2026, and 47.74% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 55.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.43% |
| Mar 31, 2026 | 52.79% |
| Dec 31, 2025 | 47.74% |
| Sep 30, 2025 | 49.05% |
| Jun 30, 2025 | 48.70% |
| Mar 31, 2025 | 49.44% |
| Dec 31, 2024 | 53.34% |
| Sep 30, 2024 | 35.51% |
| Jun 30, 2024 | 22.82% |
| Mar 31, 2024 | 2.06% |
| Dec 31, 2023 | 25.29% |
| Sep 30, 2023 | 943.75% |